Codiak Biosciences Gross Profit

The latest gross profit for CDAK is $34M as of September 2022. That compares with $17M in the prior-year period — up 98.9% year over year. That is below the Healthcare sector average of $67B. Investors often review this figure alongside Codiak Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, CDAK's gross profit moved from $17M to $34M — a 98.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Codiak Biosciences's operating scale or balance-sheet position.

Against Healthcare companies, CDAK currently prints $34M for gross profit, while the sector average sits near $67B. That is roughly 99.9% below the sector mean. Large gaps often invite a closer look at Codiak Biosciences's growth, margins, and balance sheet.

A gross profit figure of $34M for CDAK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $67B. Explore the charts below for those layers of context.

After noting CDAK's gross profit ($34M), review year-over-year change from $17M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.